openPR Logo
Press release

RNA Therapeutics Market Future Trends, New Opportunities, Business Growth, Share, Global Size, Demand, Key Segments And Forecast

12-13-2024 08:42 PM CET | Health & Medicine

Press release from: ABNewswire

The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US)

The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US)

Browse 135 market data Tables and 36 Figures spread through 171 Pages and in-depth TOC on "RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028
RNA Therapeutics Market [https://www.marketsandmarkets.com/Market-Reports/rna-therapeutics-market-235963408.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] in terms of revenue was estimated to be worth $13.7 billion in 2023 and is poised to reach $18.0 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028 according to a new report by MarketsandMarkets Trademark . Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (saRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics. saRNAs are 21-nucleotide long double-stranded RNAs (dsRNAs) complementary to the promoter region of a targeted gene. They can upregulate gene expression, potentially correcting deficiencies associated with genetic disorders and re-activating tumor suppressor genes in multiple types of cancers. On the other hand, the discontinuation/recalls of RNA therapeutic products is expected to hinder market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235963408 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

The vaccines segment accounted for the largest share of the RNA therapeutics market in 2022.

Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented majority of the market share and is anticipated to maintain this dominance throughout the forecast period. Two key vaccine products that have showcased majority revenue contribution in this segment, include Spikevax (Moderna, Inc.) and Comirnaty (Pfizer, Inc.) vaccines. Additionally, these COVID-19 vaccines showcased a considerable revenue growth between from 2021 and 2022. On the other hand, the recent recall/discontinuation of Spikevax (Moderna, Inc.) is anticipated to hinder the revenue growth post 2022. Increase in the development of innovative RNA medicine companies in the RNA therapeutics market has rendered it the fastest growing segment during the forecast period.

The RNA interference (RNAi) therapeutics segment is expected to grow at the highest CAGR from 2023 to 2028.

Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. Factors associated with RNA interference (RNAi) therapeutics such as precision and versatility have increased the potential of RNAi applications in personalized medicine and other clinical applications. On the other hand, the mRNA therapeutics segment accounted for the highest share in the global market in 2022 and is expected to maintain this trend through 2021-2028. The advantages of mRNA over DNA or proteins/peptides coupled with advent of novel vaccine and molecular entities are the key attributive reason to this dominance.

The infectious diseases segment accounted for the largest share in the RNA therapeutics market in 2022.

Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. The large share of the infectious diseases segment is a result of the rapid developments in RNA vaccine manufacturing capabilities for the treatment of infectious diseases along with the outbreak of COVID-19. Demand for mRNA vaccines grew significantly through 2021-2022, for immunization against SARS-COV-2 infection.

Increase in the use of RNA-based therapeutics for the treatment of rare/genetic disorders contributes to the high share of hospitals & clinics.

The RNA therapeutics market is segmented into hospitals and clinics and research settings. The growing use of RNA therapeutics across hospitals and clinics is driven by factors such as the increasing understanding and advancements of RNA-based therapeutics, the growing number of trends in personalized medicine, the increasing prevalence of chronic diseases, and the rising research investments by governments, private foundations, and industry stakeholders.

Europe dominates the global RNA therapeutics market throughout the forecast period.

The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with highest share of revenue in this segment in 2022. North America has emerged as the fastest growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs is highest in 2022, and this is set to continue through the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=235963408 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

RNA Therapeutics Market Dynamics:

Drivers:

1. Increasing partnerships and collaborations among market players and RNA technology manufacturers

Restraints:

1. Discontinuation or recalls of RNA therapeutic products

Opportunities:

1. Higher progress in the development of RNA aptamer-based therapeutics

Challenge:

1. Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA

Key Market Players:

The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Sanofi (France), Arrowhead Pharmaceuticals, Inc. (US), BioNtech SE (Germany), Orna Therapeutics (US), CRISPR Therapeutics (Switzerland), Silence Therapeutics (UK), Astellas Pharma Inc. (Japan), CureVac SE (Germany), Sirnaomics (US), Arcturus Therapeutics Inc. (US) and Arbutus Biopharma (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=235963408 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

RNA Therapeutics Market Advantages:

* Precision Medicine: RNA-based therapies can be tailored to target specific genetic mutations or disease pathways, allowing for personalized treatments that are more effective and have fewer side effects.
* Speed of Development: The rapid development of RNA-based vaccines during the COVID-19 pandemic demonstrated the agility of this technology, which can potentially accelerate the response to emerging diseases and medical challenges.
* Versatility: RNA can be engineered to address a wide range of diseases, including genetic disorders, cancer, infectious diseases, and rare diseases, making it a versatile platform for therapeutic development.
* Reduced Off-Target Effects: Compared to traditional small molecule drugs, RNA therapies can have a higher degree of specificity, minimizing off-target effects on healthy cells and tissues.
* Lower Manufacturing Costs: Advances in RNA synthesis and production techniques are driving down manufacturing costs, potentially making RNA therapies more accessible and affordable.
* Targeting Undruggable Proteins: RNA therapeutics can target proteins that were previously considered "undruggable" with small molecules, expanding the range of potential drug targets.
* Potential for Gene Editing: RNA-based therapies, such as CRISPR-Cas9, hold promise for precise gene editing and the treatment of genetic diseases at their root cause.
* Immunomodulation: RNA molecules can be designed to stimulate or inhibit immune responses, making them valuable tools in the treatment of autoimmune diseases and for enhancing cancer immunotherapies.
* Reduced Development Risk: The ability to rapidly iterate and optimize RNA therapies in preclinical and clinical stages can reduce the risks associated with drug development.
* Therapeutic Innovation: RNA therapeutics represent a novel class of drugs that can complement existing treatment modalities, offering innovative solutions to unmet medical needs.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rna-therapeutics-market-future-trends-new-opportunities-business-growth-share-global-size-demand-key-segments-and-forecast]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/rna-therapeutics-market-235963408.html



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNA Therapeutics Market Future Trends, New Opportunities, Business Growth, Share, Global Size, Demand, Key Segments And Forecast here

News-ID: 3787595 • Views:

More Releases from ABNewswire

Energy Management Systems Market Share Expected to Reach $84.34 billion by 2029
Energy Management Systems Market Share Expected to Reach $84.34 billion by 2029
The global energy management systems market share is expected to grow from estimated $49.01 billion in 2025 to $84.34 billion by 2029, at a CAGR of 13.8% during the forecast period. The global Energy Management Systems Market [https://www.marketsandmarkets.com/Market-Reports/energy-management-systems-ems-market-1189.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=EMS] share is expected to grow from USD 49.01 billion in 2025 to USD 84.34 billion by 2029, at a CAGR of 13.8% during 2025-2029. Rising energy costs, integration of renewable sources for power
Identity Verification Market Advancements Highlighted by Analysis and Forecast to 2028: Opportunities, Trends, and Outlook
Identity Verification Market Advancements Highlighted by Analysis and Forecast t …
Identity Verification Market by Offering (Solutions and Services), Type (Biometric and Non-Biometric), Organization Size, Deployment Mode, Application, Vertical (BFSI, Retail & eCommerce, and Gaming & Gambling) and Region - Global Forecast to 2028 The global identity verification market [https://www.marketsandmarkets.com/Market-Reports/identity-verification-market-178660742.html?utm_campaign=identity-verification-market&utm_source=abnewswire.com&utm_medium=paidpr] will be valued at approximately USD 10.9 billion in 2023 and is expected to grow to USD 21.8 billion by 2028, reflecting a CAGR of 14.9% during the forecast period. The rising
Latent TB Testing Market to Hit USD 773.4 Million by 2029 with 5.8% CAGR | MarketsandMarkets Trademark
Latent TB Testing Market to Hit USD 773.4 Million by 2029 with 5.8% CAGR | Marke …
The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US), bioMerieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), invitros (South Korea), Serum Institute of India Pvt. Ltd. (India) The global [https://www.marketsandmarkets.com/Market-Reports/latent-tb-testing-market-125200332.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=latenttbtestingmarket] is expected to grow to USD 773.4 Million by 2029, up from USD 582.5 Million in 2024, at a CAGR of 5.8% over the forecast period.
Ignite SEO Expands Service Offering with White Label SEO Solutions
Ignite SEO Expands Service Offering with White Label SEO Solutions
Ignite SEO has launched its white label SEO services, allowing agencies and businesses to resell expert SEO solutions under their own brand. London, UK - 11th February, 2025 - Ignite SEO, a premier UK-based SEO agency, is proud to introduce its latest service: white label SEO services [https://www.igniteseo.co.uk/white-label-seo-services/]. This new offering allows agencies, consultants, and marketing firms to provide high-quality SEO solutions under their own brand, backed by Ignite SEO's proven

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and